Effectiveness of Baricitinib in Treating Atopic Dermatitis in Difficult-to-treat Areas: A Retrospective Real-world Study
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0386Keywords:
Atopic dermatitis, Baricitinib, Difficult-to-treat areas, Real-world study, Quality of lifeDownloads
References
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet 2020; 396: 345–360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
Napolitano M, Potestio L, Pezzolo E, Rossi M, Saboya R, Galli B, et al. Efficacy of abrocitinib and baricitinib on “difficult-to-treat areas” in patients with atopic dermatitis: a multicentre study. Clin Exp Dermatol 2025; 50: 863–865. DOI: https://doi.org/10.1093/ced/llae415
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242–255. DOI: https://doi.org/10.1111/bjd.18898
Gori N, Di Nardo L, Ippoliti E, Antonelli F, Boeti L, Balato A, et al. Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors. J Dermatolog Treat 2025; 36: 2578249. DOI: https://doi.org/10.1080/09546634.2025.2578249
Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat 2022; 33: 1521–1530. DOI: https://doi.org/10.1080/09546634.2020.1839008
Reguiai Z, Becherel PA, Perrot JL, Fougerousse AC, Begon E, Poreaux C, et al. Impact of baricitinib on patients’ quality of life after one year of treatment for atopic dermatitis in real-world practice: results of the observatory of chronic inflammatory skin diseases registry. Acta Derm Venereol 2023; 103: adv14153. DOI: https://doi.org/10.2340/actadv.v103.14153
Lauletta G, Patruno C, Brescia C, Cosenza A, D’Elia C, Ventura V, et al. Head and neck dermatitis in atopic dermatitis: a narrative review of pathogenesis, clinical challenges, and therapeutic strategies. Antibodies 2025; 14: 104. DOI: https://doi.org/10.3390/antib14040104
Holness DL, Beaton D, Harniman E, DeKoven J, Skotnicki S, Nixon R, et al. Hand and upper extremity function in workers with hand dermatitis. Dermatitis 2013; 24: 131–136. DOI: https://doi.org/10.1097/DER.0b013e3182910416
Woo YR, Han Y, Lee JH, Lee YB, Kim JE, Kim M, et al. Real-world prevalence and burden of genital eczema in atopic dermatitis: a multicenter questionnaire-based study. J Dermatol 2021; 48: 625–632. DOI: https://doi.org/10.1111/1346-8138.15817
Misery L, Seneschal J, Reguiai Z, Merhand S, Héas S, Huet F, et al. The impact of atopic dermatitis on sexual health. J Eur Acad Dermatol Venereol 2019; 33: 428–432. DOI: https://doi.org/10.1111/jdv.15223
Napolitano M, Fabbrocini G, Kastl S, Battista T, Di Guida A, Martora F, et al. Effect of dupilumab on sexual desire in adult patients with moderate to severe atopic dermatitis. Medicina 2022; 58: 1708. DOI: https://doi.org/10.3390/medicina58121708
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
